Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

8.210 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday
Via Benzinga
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Aurinia Pharmaceuticals Stock Is Glowing Green Today
Investors appear to be cheering another patent win by the company. 
Via The Motley Fool
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Preview: Aurinia Pharmaceuticals's Earnings
Via Benzinga
Why Shares of Aurinia Pharmaceuticals Soared This Week
A patent settlement and improved financials sent the stock soaring. 
Via The Motley Fool
3 Stocks That Already Doubled in 2023 and Could Keep Climbing
The gains these stocks notched in the first few months of the year could be the beginning of a much longer bull run. 
Via The Motley Fool
What's Going On With Aurinia Pharmaceuticals Stock Wednesday?
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher Wednesday after the company announced "promising results" from its AURORA 
Via Benzinga
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
Via Benzinga
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What's Going On With Aurinia Pharmaceuticals Stock Today?
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales fig 
Via Benzinga
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
These 2 Healthcare Stocks Have Doubled in 2023
Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks. 
Via MarketBeat
Aurinia Announces PTAB Has Terminated Inter Partes Review
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tesla, Amazon, Apple, Aurinia Pharma, Vera Therapeutics: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed in the red on Tuesday, the first trading day of 2023, as concerns over rising rates and inflation still seem to drive investor sentiments. 
Via Benzinga
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. 
Via Benzinga
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed the following analyst ratings within the last quarter: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.